Drug intelligence / Profile preview

PNC-009

Development stage: Preclinical
Lead developer: ProEncia Biotechnology
Modality: Small Molecules
Administration: Topical

Overview

PNC-009 is a prescription-strength (RX) topical formulation developed by ProEncia Biotechnology for the treatment of acute and chronic periodontal gum disease. It is designed for short-term application to address and reduce the pathogenic bacterial load in the oral cavity. PNC-009 is part of a suite of periodontal treatments that includes PNC-007 (a similar formulation for long-term use) and over-the-counter products PNC-004 and PNC-005. The therapy aims to manage the underlying bacterial causes of gum inflammation and tissue destruction.

Beyond the preview

Go deeper on PNC-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNC-009.

Explore the full profile